Both candidates in the DAYBREAK trial met their primary endpoints, positioning the company to take on the market leader in wet macular degeneration.
Kodiak Sciences said its pivotal DAYBREAK Phase 3 trial in wet age-related macular degeneration met its primary endpoint for both drug candidates, sending the stock up about 145% on Monday.
Zenkuda, known scientifically as tarcocimab tedromer, achieved non-inferior vision gains compared with aflibercept, the established standard of care, with a p-value of 0.0007. At the one-year mark, 54% of Zenkuda patients were on a 24-week, or six-month, dosing interval.
The second candidate, KSI-501, or tabirafusp-ted, met its vision primary endpoint with a p-value of 0.0036 and a key anatomical secondary endpoint with a p-value below 0.0001.
The dosing edge
Durability is the competitive battleground in retinal disease. Patients receive injections directly into the eye, so every visit avoided matters to patients, clinicians and payers. Zenkuda patients received four monthly loading doses, then individualized intervals of four to 24 weeks, governed by strict retreatment rules that required the retina to stay dry. Having more than half of patients reach the six-month maximum under those conditions is the headline commercial claim.
Safety profile
The safety numbers are equally important for a drug class that has been hurt by inflammation concerns. Zenkuda showed a 0% rate of intraocular inflammation and a 0.5% rate of cataract adverse events, compared with 0.9% for aflibercept. KSI-501 posted 0.4% intraocular inflammation and no cataracts.
Chief Executive Victor Perlroth said the results position the company "for the next stage of Kodiak's evolution, as we prepare for the planned commercialization of Zenkuda."
What the market priced
A 145% one-day move is the market's way of saying it had assigned a low probability to success. Non-inferiority is a lower bar than superiority, so the rally rests less on vision gains beating aflibercept and more on matching it with fewer injections and a clean safety record.
That framing sets up the next set of questions. Physicians will want to see whether the six-month cohort holds its vision gains in the second year, and payers will want to know whether fewer injections translate into lower total treatment costs.
The next milestone is the regulatory filing for Zenkuda. Its timing and the second-year durability data will determine whether Kodiak can convert a trial win into share in a market where the incumbents already offer extended dosing.